NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,462.42 +255.29 (+1.40%) CRUDE OIL
79.19 +0.24 (+0.30%) GOLD FUTURES
2,315.50 +5.90 (+0.26%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,453.32 +1,833.71 (+4.02%)
Viridian Therapeutics, Inc. (0K1R.L)
- Business Wire
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
WALTHAM, Mass., April 29, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial results and recent business highlights.
- Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 04, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 102,000 shares of the company’s common stock to th
- Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
WALTHAM, Mass., March 05, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
